par Umubyeyi, Alaine Nyaruhirira;Rigouts, Leen;Shamputa, Isdore Chola;Dediste, Anne ;Struelens, Marc ;Portaels, Françoise
Référence International journal of infectious diseases, 12, 2, page (152-156)
Publication Publié, 2008-03
Référence International journal of infectious diseases, 12, 2, page (152-156)
Publication Publié, 2008-03
Article révisé par les pairs
Résumé : | Background: Multidrug-resistant tuberculosis (MDR-TB) has become a therapeutic problem in many parts of the world, necessitating the inclusion of second-line anti-tuberculosis drugs in specific treatment regimens. Methods: We studied the susceptibility of 69 MDR Mycobacterium tuberculosis isolates from Rwanda to second-line drugs by the BACTEC 460 method. Results: The results showed that 62 (89.9%) were resistant to rifabutin while a low rate (4.3%) of resistance was registered for ofloxacin; there was one case (1.4%) of resistance each for para-aminosalicylic acid, kanamycin, ethionamide, and clarithromycin. Conclusions: This information is important for devising an appropriate treatment regimen for MDR-TB patients in order to stop the spread of MDR strains and contain the acquisition of additional drug resistance in Rwanda. © 2007 International Society for Infectious Diseases. |